Quick guide
Key considerations & decision points

Who to prioritize

  • patients on polypharmacy high‑risk medications
  • anticoagulants, psychotropics, and opioids
  • recurrent infections
  • frequent antibiotic exposure

When
to act

  • at admission
  • medication reconciliation
  • transitions of care
  • before initiating high‑risk antibiotics or chronic therapies

Decision
points

  • define trigger rules for testing
  • assign pharmacist/MD review
  • decide EHR visibility (discrete PGx fields vs. PDF)

Actionable
genotype
guidance

Returns drug‑gene interpretations and alternative drug/dose recommendations to reduce drug–gene interactions. This directly lowers ADE risk and supports safer prescribing.

Antibiotic
stewardship
alignment

PGx can flag genetic risks:

  • for antibiotic toxicity and immune reactions, helping clinicians choose narrower, effective agents
  • reduce unnecessary broad‑spectrum use
  • an expectation in CMS and Joint Commission stewardship guidance

Quality
& safety
impact

  • fewer ADEs
  • optimized antibiotics reduce readmissions
  • minimize C. difficile risk
  • reduce safety events that factor into public reporting and regulatory reviews
long-term care facility team reviewing report

Implementation checklist

  • Policy & Governance: add PGx to medication safety and stewardship charters; assign clinical lead.
  • Testing Criteria: adopt triggers (polypharmacy, high‑risk meds, recurrent infections).
  • Lab & Turnaround: select validated PGx panel with ≤72‑hour turnaround for inpatient impact.
  • EHR Integration: map discrete PGx results to medication decision support; create pharmacist alert workflows.
  • Clinical workflow: require pharmacist review for actionable results; document changes in med reconciliation.
  • Education & metrics: train clinicians; track ADEs, antibiotic use metrics, and stewardship KPIs.

Risks, limitations & citations

Not all drugs have actionable PGx guidance:

  • results must be interpreted in a clinical context
  • EHR visibility and turnaround time are critical to impact
  • Poor integration reduces benefit

Regulatory expectations now require robust stewardship programs:

  • PGx is a supportive tool, not a substitute for core stewardship activities.
lab technician swab test

Key Metrics of IQRx System’s Impact

Explore how our IQRx System enhances patient care and operational efficiency.

1,000
Patients Served
$2M+
Cost Savings
Gene Variants Discovered
in the first 30 days of 2026
  • “Testimonials serve as a persuasive form of social proof, providing clear evidence of a product or service’s value. Their immense power lies in their ability to inspire trust, cultivating confidence in potential customers.”
    Dr. Sarah Johnson
long-term care patient in wheelchair with nurse

Add a short headline

Reduce Adverse Drug Events

Antibiotic Stewardship Follow-through

Increase Medication Optimization

Participation in Regulatory Alignment

By default, this panel is concealed and appears when the user clicks on the section title. Input relevant information about its title using paragraphs or bullet points. Accordions can enhance the user experience when utilized effectively. They allow users to choose what they want to read and disregard the rest. Accordions are often utilized for frequently asked questions (FAQs).

Learn more

By default, this panel is concealed and appears when the user clicks on the section title. Input relevant information about its title using paragraphs or bullet points. Accordions can enhance the user experience when utilized effectively. They allow users to choose what they want to read and disregard the rest. Accordions are often utilized for frequently asked questions (FAQs).

Learn more

Our mission is simple: help facilities make every dose count by tailoring therapy to each resident’s genetic profile. Resolve MDX turns complex data into clear, actionable insights for better care and measurable financial impact.

Connect Today, Start Saving Tomorrow!